A tariff refund lifted Thermo Fisher's quarter more than its full-year outlook

Thermo Fisher Scientific sells scientific technologies and laboratory supplies, along with pharmaceutical services such as outsourced clinical research and drug manufacturing. In the September 2026 quarter its adjusted earnings per share, which leave out costs such as amortisation of acquired intangible assets, rose 15% to $6.68, and it lifted its full-year adjusted EPS range to $25.13 to $25.43. Management's own breakdown of the quarter shows that part of the gain came from a one-time item, and that the new annual range keeps only a small part of it.

The item is a tariff refund. According to the chief financial officer, James Meyer, the company won approval during the quarter for most of its claims to recover tariffs it had paid. After money it put straight back into the business, the refund added about $60 million to adjusted operating income, or half a percentage point of margin, and none of it was in earlier guidance. It returns part of a cost the company had reported as a drag: in April it put the hit from tariffs and related currency moves to first-quarter adjusted operating margin at 80 basis points.

Adjusted operating margin was 24.5% last quarter, against 23.3% a year earlier. Taking out management's half-point for the refund leaves about 24.0%, a calculation from the reported margin. That still leaves a gain of about 0.7 points on a year earlier, by our calculation, compared with 0.4 points over the first half of the year and 0.9 points in the second quarter.

That breakdown explains why a quarter that came in 26 cents ahead of the company's previous guidance moved the annual midpoint up by only 15 cents. Operations contributed about the same to both. The refund's share fell because the company plans to spend about $40 million more in the fourth quarter on top of what it had already reinvested in the third. Meyer described it this way: "The onetime nature of the refunds provided us a unique opportunity to make incremental short-term investments".

The annual range also implies a figure for the fourth quarter. Subtracting nine-month adjusted EPS from the new midpoint leaves about $7.13 for the last quarter of the year, growth of roughly 8.5% on a year earlier by that calculation, well below the pace of the third quarter.

Revenue shows a similar pattern. Organic growth, which leaves out acquisitions, disposals and currency, was 6% last quarter, yet the company kept its fourth-quarter organic guidance at 4%. Meyer said some pharma-services customer work had been completed in the third quarter, and that momentum elsewhere in the business would make up for it in the fourth.

The range may prove cautious. Management raised its organic growth outlook for the second half after the third-quarter beat but left the fourth quarter where it was, and a stronger finish would make the implied figure look low. What the evidence shows today is narrower: part of the third quarter's growth came from a refund that management itself describes as one-time, and the company plans to spend most of the net benefit in the fourth quarter instead of carrying it into the year's earnings.